BioAge Labs
PublicBioAge Labs is now publicly traded
The data on this page reflects BioAge Labs's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 25, 2024
Last Round
Follow-on Offering
Jan 21, 2026
Est. Valuation at Exit
$861.3M
Total Funding Raised
$634.8M
Company Overview
BioAge Labs is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
Sector
Business Products and Services (B2B)
AI Layer
Application
Keywords
BioAge Labs Comparables
Compare BioAge Labs with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Variant Bio | 80% | |
| Energesis Pharmaceuticals, Inc. | 74% | |
| Metsera | 74% |
For institutional investors. Book with your work email.
BioAge Labs Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jan 21, 2026 | ||||
| Private Placement | Sep 27, 2024 | ||||
| IPO | Sep 25, 2024 | ||||
| Series D | Feb 13, 2024 | ||||
| Series C | Dec 3, 2020 | ||||
Series B | Jan 24, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioAge Labs Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, IPO, Series D, Series A, Series C |
| Jefferies | IPO |
| Longitude Capital | Series D |
| RA Capital Management | IPO, Series D |
| SV Health Investors | Series D |
| AARP | Series C |
| Lilly Ventures | Series D |
For institutional investors. Book with your work email.
BioAge Labs Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.